Align Technology (ALGN) Up 3.6% Since Last Earnings Report: Can It Continue?

Align Technology (ALGN) shares have risen 3.6% since its last earnings report, underperforming the S&P 500, while estimates have trended downward. The stock holds a Zacks Rank #3 (Hold), suggesting an expected in-line return in the coming months. In comparison, Labcorp (LH), another stock in the same industry, has gained 2.3% over the past month, reporting a 5.3% year-over-year revenue increase to $3.35 billion and EPS of $3.84.

Analysis

Align Technology (ALGN) shares have appreciated by 3.6% in the month following its last earnings report, a gain that nevertheless underperformed the broader S&P 500 index. This price increase has occurred amidst a period where analyst earnings estimates for ALGN have trended downwards. The company currently holds a Zacks Rank #3 (Hold), suggesting expectations for an in-line return relative to the market over the next few months. Align Technology's fundamental picture is further nuanced by its VGM Scores: an average Grade C for Growth and Value, but a lagging Grade D for Momentum, culminating in an overall VGM Score of C. For comparison, Labcorp (LH), another company within the Zacks Medical - Dental Supplies industry, experienced a 2.3% share price increase over the past month and also holds a Zacks Rank #3 (Hold) and a VGM Score of C. Labcorp's most recent quarterly results, reported over a month ago for the period ending March 2025, showed revenues of $3.35 billion, a 5.3% year-over-year increase, and earnings per share of $3.84, up from $3.68 a year prior, though its consensus estimate has seen a minor -0.2% downward revision in the last 30 days.

Key Decisions for Investors

• Given Align Technology's recent share price underperformance relative to the S&P 500, downward trending earnings estimates, and a Zacks Rank #3 (Hold), investors might consider maintaining a neutral or 'Hold' position.
• Closely monitor upcoming earnings announcements and further analyst estimate revisions for ALGN, as these will be key indicators for assessing whether the recent modest share price gains can be sustained or if a pullback is more probable.
• Evaluate ALGN's performance and outlook in the context of the broader Medical - Dental Supplies industry, where peers like Labcorp also exhibit moderate recent gains and 'Hold' ratings, suggesting a cautious but stable near-term environment for the sector.